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3) The prognosis of relapsed Ewing sarcoma family of tumor (ESFT) continues to be miserable. In such cases, the purpose of treatment should be palliative care. We report a case of a boy with relapsed EFST who was treated with irinotecan hydrochloride. This treatment was able to provide him with a transient improvement of quality of life. Irinotecan was administered at a dose of 40 mg/m 2 /day for three consecutive days. Thereafter, it was stopped for four days and was subsequently administered for an additional three days. This course was repeated in 21-28 days cycles. We were able to observe an improvement of images using technetium-99m-bone scans. We did not observe any signs of new tumor lesions for up to five months. The pain was relieved and no serious adverse effects were observed. While the efficacy of irinotecan remains to be confirmed, in many cases, irinotecan can be effective for relapsed ESFT. Fig. 2-A) 50 Gy VCR DXR CPA (VDC) 27
( Fig. 2-B th week after a relapse showed accumulations at rt. ribs, rt clavicle, lt. tempolar bone and parietal bones. C: The imaging of 32 nd week after a relapse showed no accumulation. : bone metastatic legion which was not treated with irradiation. : bone metastatic legion which was treated with irradiation. Fig. 1 The treatment course after a relapse in this case. IE: combination chemotherapy with ifosfamide and etoposide. ICE: combination chemotherapy with ifosfamide, carboplatin and etoposide. VDC: combination chemotherapy with vincristine, doxorubicine and cyclophosphamide. : bone metastatic legion which was not treated with irradiation.
: bone metastatic legion which was treated with irradiation.
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